

ABSTRACT

The use of an IP₃ receptor-mediated calcium channel blocker for treating a variety of diseases is herein described. Specifically, the IP₃ receptor-mediated calcium channel blocker prevents activation of the transcription factor NF-κB. As a consequence, the IP₃ receptor-mediated calcium channel blocker is used as a treatment for diseases and disorders requiring NF-κB activation, for example, inflammatory diseases, some viral infections and some unregulated growth disorders.